ANTX
AN2 Therapeutics, Inc.
$4.50
-0.13 (-2.81%)
At close · Jul 10
Market Cap
$162.07M
Shares
36,016,161
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| Investor Event Transcript | 2026-06-30 | — | |
| 8-K | 2026-06-09 | 2026-06-03 | |
| 8-K | 2026-06-04 | — | |
| 8-K | 2026-05-11 | — | |
| 10-Q | 2026-05-11 | 2026-03-31 | |
| DEF 14A | 2026-04-22 | — | |
| 8-K | 2026-04-09 | — | |
| 8-K | 2026-03-20 | 2026-03-19 | |
| 10-K | 2026-03-17 | 2025-12-31 | |
| 8-K | 2026-03-17 | — | |
| 8-K | 2026-03-10 | 2026-03-08 | |
| 8-K | 2026-01-29 | 2026-01-26 | |
| 8-K | 2025-11-12 | — | |
| 10-Q | 2025-11-12 | 2025-09-30 | |
| 10-Q | 2025-08-12 | 2025-06-30 | |
| 8-K | 2025-08-12 | — | |
| 8-K | 2025-06-20 | 2025-06-17 | |
| 8-K | 2025-06-11 | — | |
| 8-K | 2025-05-27 | 2025-05-22 | |
| 8-K | 2025-05-13 | — | |
| 10-Q | 2025-05-13 | 2025-03-31 | |
| 8-K | 2025-05-01 | — | |
| DEF 14A | 2025-04-10 | — | |
| 10-K | 2025-03-25 | 2024-12-31 | |
| 8-K | 2025-03-25 | — | |
| 10-Q | 2024-11-13 | 2024-09-30 | |
| 8-K | 2024-11-13 | — | |
| 8-K | 2024-11-05 | 2024-11-04 | |
| 8-K | 2024-08-19 | 2024-08-15 | |
| 10-Q | 2024-08-13 | 2024-06-30 | |
| 8-K | 2024-08-13 | — | |
| 8-K | 2024-08-08 | 2024-08-07 | |
| 8-K | 2024-06-24 | 2024-06-19 | |
| 10-K/A | 2024-05-14 | 2023-12-31 | |
| 8-K | 2024-05-14 | — | |
| 10-Q | 2024-05-14 | 2024-03-31 | |
| DEF 14A | 2024-04-26 | 2024-06-19 | |
| 10-K | 2024-03-29 | 2023-12-31 | |
| 8-K | 2024-03-28 | — | |
| 8-K | 2024-02-12 | — | |
| 10-Q | 2023-11-09 | 2023-09-30 | |
| 8-K | 2023-11-09 | — | |
| 8-K | 2023-09-13 | — | |
| 8-K | 2023-09-08 | 2023-09-01 | |
| 8-K | 2023-08-16 | 2023-08-15 | |
| 8-K | 2023-08-10 | — | |
| 10-Q | 2023-08-10 | 2023-06-30 | |
| 8-K | 2023-06-09 | 2023-06-07 | |
| 8-K | 2023-05-11 | — | |
| 10-Q | 2023-05-11 | 2023-03-31 |
Showing 1–50 of 62 filings